^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

FIVE-YEAR REAL-WORLD DATA ON ACUTE MYELOID LEUKEMIA: RETROSPECTIVE STUDY FROM PUBLIC HEALTH CENTER IN BRAZIL

Published date:
05/11/2023
Excerpt:
To assess effectiveness (Eligible to the Next Treatment-ENT CR and suficient performance status to the nexttreatment, PFS and OS) and security (Early Mortality) of cytarabine and anthracycline (“7 + 3”regimen)….Subgroups analyzed were about FTL3 and NPM1 mutations....It was a retrospective analysis of all the cases of non-promyelocytic AML ....There were 21% and 11% patients with FLT3-ITD and NPM1 mutations, respectively....The median of PFS and OS were 3.6 and 8.2 months respectively. Patients with FLT3mutation, platelet < 20.000 and leukocytes < 10.000 had poor outcomes....Patients with FLT3 mutation, platelet < 20.000 and leukocytes < 10.000 had poor outcomes.
Secondary therapy:
Chemotherapy